RETRACTED: Oxaliplatin activates P53/miR‐34a/survivin axis in inhibiting the progression of gastric cancer cells
Immunity, Inflammation and Disease · 2024
DOI: 10.1002/iid3.70004 ↗Kurz gefasst
Zurückgezogene Publikation in der Zeitschrift Immunity, Inflammation and Disease, 2024. Verfasst von Qiang Guo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, The First Affiliated Hospital of Baotou Medical College, Baotou, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, MicroRNAs, Oxaliplatin, Survivin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Inner Mongolia Autonomous Region.
Abstract (Originalsprache)
Introduction
The purpose of this research was to determine how the P53/microRNA‐34a (miR‐34a)/survivin pathway contributes to oxaliplatin‐induced (L‐OHP) cell inhibition in gastric cancer.
Methods
The BGC‐823 gastric cancer cells were selected, and we examined their viability following treatment with L‐OHP at different concentrations and time periods. The expression levels of miR‐34a, P53, and survivin in the cells were determined.
Results
In the 12‐ and 24‐h groups, drug concentration of 15 μg/cm² ( p < .005 in both) significantly lowered cell viability. In comparison to the control group, miR‐34a mRNA expression, P53 mRNA expression, and protein expression were all significantly greater in the 24‐h group ( p = .0324, p = .0069, p = .0260, respectively), but survivin mRNA and protein expressions were significantly lower than those in the control group ( p = .0338, p = .0032, respectively). There was a significant decrease in gastric cancer cells in the miR‐34a overexpression group ( p = .0020), a significant increase in P53 mRNA and protein expression compared to the control group ( p = .0080, p = .0121, respectively), and a significant decrease in survivin mRNA and protein expression compared to the control group. ( p = .0213, p = .0069, respectively).
Conclusion
Oxaliplatin inhibits tumor growth, invasion, and metastasis by upregulating miR‐34a, activating the expression of the upstream P53 gene, and driving the downregulation of survivin (P53/miR‐34a/survivin axis) in BGC‐823 gastric cancer cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, The First Affiliated Hospital of Baotou Medical College, Baotou, China.
- Department of Gastrointestinal Surgery, Qi Lu Hospital of Shandong University, Jinan, China.
- Department of General Surgery, HeNan RongJun Hospital, Xinxiang, China.
ORCID-Profile: Qing-Si He
Förderung
- Natural Science Foundation of Inner Mongolia Autonomous Region
Zitieren
APA
Guo, Q., Wang, X. Y., Zhai, Y. C., Dong, Y. W., & He, Q. S. (2024). RETRACTED: Oxaliplatin activates P53/miR‐34a/survivin axis in inhibiting the progression of gastric cancer cells. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.70004
Vancouver
Guo Q, Wang XY, Zhai YC, Dong YW, He QS. RETRACTED: Oxaliplatin activates P53/miR‐34a/survivin axis in inhibiting the progression of gastric cancer cells. Immunity, Inflammation and Disease. 2024. doi:10.1002/iid3.70004
BibTeX
@article{Guo2024,
author = {Guo, Qiang and Wang, Xin-Yuan and Zhai, Yan-Chang and Dong, Yong-Wei and He, Qing-Si},
title = {RETRACTED: Oxaliplatin activates P53/miR‐34a/survivin axis in inhibiting the progression of gastric cancer cells},
journal = {Immunity, Inflammation and Disease},
year = {2024},
doi = {10.1002/iid3.70004}
}
EUVIMED